SCM
CBIO

Sterling Capital Management’s Crescent Biopharma CBIO Stock Holding History

Sterling Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37K Buy
+76
New +$1.48K ﹤0.01% 3079

Other funds holding CBIO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Sterling Capital Management's CBIO Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 76 shares worth $1.37K. The stake represents ﹤0.01% of the portfolio and ranks #3079 among its holdings.

8 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Sterling Capital Management held 76 shares of Crescent Biopharma worth $1.37K as of Q2 2026.
  • Crescent Biopharma was a new Sterling Capital Management position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3079 holding.
  • 8 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.